ASCO Daily News, a publication of the American Society of Clinical Oncology (ASCO), has published an article about how “evolving perioperative management” of bladder and kidney cancers is advancing genitourinary (GU) treatment.
“The standard of care in bladder cancer treatment is evolving rapidly, with perioperative antibody-drug conjugates such as enfortumab vedotin and immunotherapy with pembrolizumab demonstrating promising results in clinical trials,” the association writes.
Read much more about these developments in ASCO’s full article.
